“In the first quarter of this year, we continued our strong progress as we fully enrolled our NSCLC EGFR PACC mutation Phase 1b cohort in our FURTHER study and initiated a Phase 1b combination study of firmonertinib and ICP-189, a SHP2 inhibitor, in NSCLC patients with EGFR classical mutations. This underscores our comprehensive development plan to maximize the potential of firmonertinib across EGFR mutant NSCLC,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “We were also proud to present data at the AACR annual meeting, which further demonstrated that firmonertinib was observed to be broadly active preclinically across a wide range of EGFR uncommon mutations in NSCLC, including PACC and exon 20 insertion mutations. We look forward to continuing building upon these milestones as we work to give cancer patients important new treatment options.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma initiated with a Buy at H.C. Wainwright
- ArriVent BioPharma Welcomes Kristine Peterson to Board
- ArriVent Appoints Kristine Peterson to its Board of Directors
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
- ArriVent BioPharma Reports Full Year 2023 Financial Results